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The primary hyperoxalurias (PHs) are rare disorders of
glyoxylate metabolism in which specific hepatic enzyme
deficiencies result in overproduction of oxalate. Due to the
resulting severe hyperoxaluria, recurrent urolithiasis or
progressive nephrocalcinosis are principal manifestations.
End stage renal failure frequently occurs and is followed by
systemic oxalate deposition along with its devastating
effects. Due to the lack of familiarity with PHs and their
heterogeneous clinical expressions, the diagnosis is often
delayed until there is advanced disease. In recent years,
improvements in medical management have been associated
with better patient outcomes. Although there are several
therapeutic options that can help prevent early kidney
failure, the only curative treatment to date is combined
liver–kidney transplantation in patients with type I PH.
Promising areas of investigation are being identified.
Knowledge of the spectrum of disease expression, early
diagnosis, and initiation of treatment before renal failure
are essential to realize a benefit for patients.
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Primary hyperoxaluria (PH) type I and type II are relatively
rare autosomal recessive inborn errors of glyoxylate metabo-
lism, which result in markedly increased endogenous oxalate
synthesis by the liver, and to a minor degree in PH II by other
body cells. Type I primary hyperoxaluria (MIM 604285) is
caused by deficient or absent activity of liver-specific
peroxisomal alanine/glyoxylate aminotransferase (AGT1). In
some patients with PH type I enzyme is present but
mistargeted to mitochondria where it is metabolically
inactive. Primary hyperoxaluria type II is a somewhat milder
but not benign variant (PHII, MIM 260000, 604296) that
occurs as a result of deficient glyoxylate reductase/hydro-
xypyruvate reductase (GRHPR) enzyme activity.2 A small
number of patients have been described with a phenotype
similar to that of PH I and PH II but with normal AGT and
GRHPR enzyme activities. The specific etiology of the
hyperoxaluria in such patients remains to be elucidated and
they are referred to as non-I, non-II PH patients.3
Among disorders causing hyperoxaluria, the PH are the
most severe, ultimately leading to end-stage renal failure
(ESRF) and if untreated, death in most of the patients.4 PH
(endogenous) must be differentiated from the more common
secondary forms. In secondary hyperoxaluria, there is either
dietary or other exposure to large amounts of oxalate or
oxalate precursors or there is an underlying disorder that
causes increased absorption of (dietary) oxalic acid from the
intestinal tract. The latter is usually characterized by fat
malabsorption. Among secondary causes of hyperoxaluria,
those attributable to gastrointestinal (GI) disease (for
example, inflammatory bowel diseases, cystic fibrosis, status
post-bariatric surgery, short bowel syndrome (SBS)) can lead
to severe hyperoxaluria due to enhanced absorption of
oxalate from the GI tract and may result in reduced renal
function. Most other forms of absorptive secondary hyper-
oxaluria are of milder degree (0.55 to o0.8 mmol/1.73 m2
per day) and usually carry a better prognosis. In contrast to
inflammatory bowel diseases or short bowel syndrome
patients with PH show oxalate absorption within normal
limits (o15%).5
Oxalate cannot be metabolized in mammals and is
primarily eliminated through the kidneys as an end product
of metabolism. Oxalate is freely filtered at the glomerulus and
also secreted by the tubules. In all types of PH, very high
urinary oxalate excretion, typically 41 mmol/1.73 m2 per day
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(normal o0.5), is observed. The urine becomes super-
saturated for calcium oxalate resulting in formation of
complexes and crystals within the tubular lumen. The crystals
attach to the surface of renal tubular cells, allowing
aggregation of crystals into stones (urolithiasis), others are
incorporated into the renal tubule cells, and some further
migrate into the renal interstitium (nephrocalcinosis), the
clinical hallmarks of the PH (Figure 1). Progressive renal
parenchymal inflammation and interstitial fibrosis from
progressive nephrocalcinosis and recurrent urolithiasis along
with secondary complications (urinary tract infection,
obstruction) cause renal impairment, which progresses to
ESRF over time.6–8 Once renal function declines to a
glomerular filtration rate (GFR) below 30–40 ml/min per
1.73 m2 body surface area, renal excretion of oxalate is
sufficiently compromised that plasma oxalate concentration
rises (normal limits 1–6 mmol/l9) and can rapidly exceed the
supersaturation threshold for calcium oxalate as levels
430 mmol/l are reached. Systemic deposition of calcium
oxalate (oxalosis) then occurs in extra-renal tissues, including
retina, myocardium, vessel walls, skin, bone, and the central
nervous system among others (Figure 2). Long-term
consequences include cardiomyopathy, cardiac conduction
disturbances, vasculopathy, heart block, treatment-resistant
anemia, oxalate osteopathy resulting in debilitating bone and
joint pain, retinopathy and if untreated, early death.4,10 Thus,
the hepatic defect, which primarily manifests within the
urogenital tract, when advanced, becomes a devastating
multisystemic disorder. Owing to the risk of systemic
oxalosis, renal replacement with dialysis or transplantation
is required earlier in patients with PH than those with renal
insufficiency from other causes. Yet, the systemic nature of
the clinical manifestations may obscure the diagnosis for
years. Awareness of PH as a possible cause and measurement
of plasma as well as urinary oxalate are essential initial steps.7
Owing to the nature of the metabolic defects in PH,
marked hyperoxaluria is present from birth, yet there is
marked heterogeneity of disease expression. Severe ‘infantile
oxalosis’ with early ESRF in PH type I occurs in some
patients, whereas others lack clinically apparent sequela well
into adulthood.4 Although PH are considered rare with a
prevalence of 0.8–2.9 per 106 populations and an estimated
incidence rate of 0.1–0.2 per 106 populations, they appear to
be under diagnosed. This is suggested by the high proportion
of patients (up to 35%) in whom diagnosis is made only after
advanced renal failure has developed or, even worse, after
early kidney graft failure from recurrent oxalosis following
isolated kidney transplantation.6–8
Early diagnosis, molecular subtyping, and prompt initia-
tion of treatment are of vital importance for PH patients.
This is best illustrated by recent clinical studies showing




Figure 1 | Radiographic findings in PH. (a-c) Typical
sonographical and X-ray findings of severe urolithiasis in patients
with primary hyperoxaluria (PH) type I aged 5, 9, and 39 years and
with still normal or only slightly impaired renal function. (d) Low
enhanced computed tomography scan showing a Staghorn
calculus and five further smaller stones in the right kidney of a 16-
year-old patient with PH, uncompliant with regard to medication
and fluid intake.
Figure 2 | Severe systemic oxalosis—calcium oxalate
depositions in the bone (osteolytic lesions, epiphyseolysis),
skin (crystal deposition at finger tip, livedo reticularis-like
picture) and retina in different patients with primary
hyperoxaluria type I.
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years, compared with earlier case series reporting a 50% risk
for ESRF by age of 15 years, and about 80% ESRF rate by age
30.6,11,12 Yet, due to lack of familiarity with the disease, and
the misconception of physicians and patients that stones are
mostly benign, delays of many years from onset of symptoms
to diagnosis are common.7,12 Onset of calcium oxalate stone
formation in childhood or adolescence, frequent recurrences
of stone disease, multiple calcium oxalate stones, or
nephrocalcinosis in patients with renal failure of any age
are important clues to the diagnosis and always warrant
metabolic screening and, if appropriate, further specific
diagnostic testing.13
The first sign or symptom is usually blood in the urine,
pain, passage of a stone, or urinary tract infection. Patients
with renal failure due to ‘infantile oxalosis’ present with
failure to thrive, anemia, and acidosis. The majority of
patients are symptomatic early in life and mostly before 10
years of age.4,6 In some cases, however, the disease may go
unrecognized either due to the absence of symptoms or to
incorrect diagnosis, until patients reach 30–50 years of age.4,12
Some patients present during adulthood with kidney failure
as the first symptom, often after earlier symptoms have been
misinterpreted.
PH TYPE I
Primary hyperoxaluria type I accounts for the majority
(70–80%) of all cases. Although disease severity and resulting
phenotype varies widely even within affected families, about
90% of all (western) PH I cases become symptomatic in
childhood to adolescence with the cardinal features being
recurrent urolithiasis and/or nephrocalcinosis.6–8,14 In some
cases, however, the disease may go unrecognized for years
either due to the absence, subtlety, or misinterpretation of
symptoms. It is important to note that deficiency of hepatic
AGT never causes liver disease. Most patients develop chronic
renal failure between 25 and 45 years of life, although renal
failure may occur as early as infancy and some patients retain
renal function into the sixth or seventh decade.
Median age at diagnosis in the Netherlands is 7.3 years.
Data from the International Registry for Primary Hyperox-
aluria reports median age for diagnosis to be 6.0 years in
patients with retained renal function compared with 23 years
in those with ESRF at the time of diagnosis.6,12 Early
diagnosis leading to appropriate clinical management
appears associated with improved overall outcome.
Primary hyperoxaluria I appears to affect about 1 in
120,000 live births in central Europe.8,11 However, the true
incidence and prevalence are unknown. In both Europe and
the United States, PH accounts for less than 1% of children
and adolescents with ESRF.4,7 The disease is seen with higher
frequency in certain parts of the world, including the
northern African countries and the Canary Islands, here
possibly due to consanguineous marriages.15 Whether there
are regional variations in disease expression remains to be
determined, although early observations are of interest.16 A
recent Japanese survey of 59 patients documented a milder
course (30% with onset of symptoms after age 25 years) than
was observed in an historical European cohort.17,18 A
substantial proportion of patients (11–30%, Japan up to
75%) are diagnosed late with symptoms of advanced renal
failure or early kidney graft failure.
Primary hyperoxaluria I is evidenced by marked clinical
heterogeneity of the disease. In addition to marked
interfamilial clinical variability yet a more remarkable
intrafamilial phenotype variation can be observed despite
identical genotype.19 In the majority of patients with PH I,
systemic oxalosis is believed to occur progressively after the
GFR decreases below 30–40 ml/min per 1.73 m2. As systemic
oxalosis produces a confusing multitude of symptoms
partially resembling rheumatoid or autoimmune disorders/
vasculitis, correct diagnosis is not uncommonly overlooked
for years. Owing to the autosomal-recessive nature of PH
type I and the importance of early diagnosis, siblings of
affected patients should always be screened. An algorithm to
assist in diagnosis has been published recently.13
GENETICS OF PH I
The single copy AGXT gene is located on chromosome
2p37.3. Its genomic sequence consists of 11 exons spanning
B10 kb, resulting in a 1.7 kb cDNA with an open reading
frame of 1176 bp. The gene product AGT is a homodimeric
protein exclusively expressed in human hepatocytes, each
43 kDa subunit containing 392 amino acids and holding one
molecule of pyridoxal-phosphate as cofactor.20 The large
N-terminal domain contains most of the catalytic active site,
the cofactor-binding site, and the dimerization interface. The
function of the smaller C-terminal domain is largely
unknown apart from containing the atypical peroxisomal
targeting sequence (PTS1, LysLysLeu) and a presumed
ancillary sequence PTS1A required for proper peroxisomal
transport.21 The crystal structure of normal AGT has been
solved and provides valuable knowledge of AGT folding and
how specific mutations and polymorphisms effect protein
folding, dimerization, and catalytic activity.22
Almost a hundred disease-causing mutations in the
AGXT gene have been reported so far. The spectrum includes
mostly point mutations leading to missense, nonsense, and a
number of splicing mistakes. Minor deletions/insertions
and a few major deletions spanning several exons, or other
complex mutations account for the remaining third.
Mutations can be found throughout the 11 exons of the
gene. Analysis limited to the four most common mutations
(c.508G4A, c.33_34insC, c.731T4C, c.454T4A) or selected
exons provides less sensitivity than liver biopsy. Nonetheless,
with whole AGXT gene sequencing becoming increasingly
available, diagnostic accuracy rivals biopsy.23,24
In Caucasians, two main haplotypes are found, named
AGT major (80% allelic frequency (AF)) and AGT minor
(20% AF). In Japan and China, the minor AF is only around
2%.25 The haplotypes differ in a number of polymorphisms
occurring in the minor allele, among them a single base-pair
change on position c.32 C4T (p.P11L). Strong linkage
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disequilibrium between these variants is observed, thus not
accidentally occurring conjointly in the minor allele. Most of
them have no relevant effect, but the P11L polymorphism
influences the function of AGT in several ways: (1) reduction
in AGT activity in vitro up to 30%, (2) impaired dimerization
of AGT subunits in vitro, and (3) introduction of a weak
N-terminal mitochondrial mistargeting sequence that directs
about 5% of the enzyme to the mitochondria.26
More than 20 polymorphisms of the AGXT gene are
reported and the relevance of some variations is still unclear.
For example c.836T4C is found compound heterozygously
with causative mutations in patients showing a PH I
phenotype, but when expressed in vitro on the AGT major
allele, this variant shows normal activity. Genotype data must
always be interpreted with regard to ethnic background of the
population served by the reporting institutions.
Although minor haplotype homozygotes show reduction
of catalytic activity, this alone is not sufficient to cause
disease in the absence of specific mutations. In addition, a
number of missense mutations (including c.508G4A) are
predicted to cause no phenotype on their own in absence of
P11L. Others have different consequences whether present on
the minor or major allele. The c.508 G4A mutation
represents the most common mutation (20–40% AF)
worldwide. In the presence of P11L, there is a synergistic
effect, resulting in slowing of the rate of AGT folding
and dimerization, which allows mitochondrial import of
unfolded AGT monomers. The insertion c33_34insC leads to
a protein truncation and is the most common mutation
found on the major allele (B12% AF in Caucasians).
Another frequently encountered missense mutation
c.731T4C (I244T, 6–9% AF) in patients from Spanish-
African descent produces functionally inactive aggregates. As
it represents the causative mutation in about 90% of PH I
patients from the Canary Islands with almost all being
homozygous, it is believed to result from a founder effect in
this population.15 Unfortunately, despite the common
genotype, affected individuals from the Canary Islands show
no uniform phenotype.
The molecular consequences of some mutations have been
studied in vitro, in the Escherichia coli system or in the mouse
model where AGT is dually expressed in the mitochondria
and peroxisomes. Caution is appropriate in extrapolating in
vitro observations to humans. Nonetheless, despite their
limitations, these first studies provided the setting for the
exploration of novel pharmacologic approaches. For exam-
ple, the two most common mutations present on the minor
allele result in conformational changes that can be modeled
in cell culture, and their consequences modified by
manipulations of culture conditions.27 Unfortunately no
studies on human hepatocytes are available, but these
investigations serve as proof of principle that the under-
standing of the molecular pathology can lead to new
therapeutic approaches.
Although mutation analysis is valuable for diagnosis,
thus far, there has been limited success in establishing
genotype–phenotype correlations. Siblings who share the
same genotype, but in whom clinical expression differs
widely have been noted in a number of families worldwide.19
Genotype–phenotype correlation has been described for some
mutations of the AGXT gene.25,28,29 Patients who are
compound heterozygous for the c.508G4A mutation appear
to respond to pharmacologic doses of pyridoxine with a
partial reduction, or in those homozygous, with a sometimes
complete normalization of urine oxalate excretion.30 While
most helpful in clinical management, partial pyridoxine
response appears insufficient for the majority of c.508G4A
heterozygotes to overcome the deleterious consequences of
the disease in the long-run. With the constitution of the
pan-European hyperoxaluria consortium (OxalEurope) join-
ing forces with the Mayo Clinic database soon more than 500
PH cases will be available for genotype–phenotype studies. By
collection of a large cohort of families and subsequent careful
analysis, we may be able to better identify genetic and
environmental modifiers responsible for the variability in
disease expression.
PH TYPE II
Type II is a monogenic, autosomal recessive disorder
predominantly affecting hepatic glyoxylate metabolism,
although GRHPR is also expressed in lesser amounts in
most body tissues.28 As a result of reduced enzyme activity,
increased amounts of glyoxylate and hydroxypyruvate are
available for conversion by lactate dehydrogenase to both
oxalate and L-glyceric acid. Excessive amounts of both
metabolites are excreted by the kidney. The hyperoxaluria
leads to recurrent nephrolithiasis and less frequently,
nephrocalcinosis. An asymptomatic clinical course for many
years or unilateral presentation of stones initially with calculi
appearing in the contra-lateral kidney only after nephrectomy
or late in the course is not uncommon.7,31 Until the late
1990s, only about 30 cases have been reported in the
literature. Now with better awareness and molecular
diagnostic tools available this entity is recognized more often.
Although the clinical course can be very similar to PH
type I, patients with type II PH appear to have less severe
stone formation, as well as less nephrocalcinosis and better
preservation of renal function over time when compared with
patients with type I disease.32 Thus, far no case of infantile
renal failure with oxalosis resulting from GRHPR deficiency
has been reported. Taking the small numbers and therefore
the relative paucity of long-term data into account, there is
still a risk of renal impairment. Once severe renal impairment
is reached, the patient is also at a high risk for systemic
oxalosis.
The GRHPR gene is located on chromosome 9 (9p11) and
consists of 9 exons, which encode a 328 amino-acid (36 kDa)
protein. To date, 15 causative mutations in the GRHPR gene
have been described, with the one base pair deletion G
(c.103delG) in exon 2 being the most common in patients of
Caucasian descent (AF of approximately 40%). The spectrum
of mutations identified includes deletions, insertions,
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missense, and nonsense mutations, all resulting in loss of
protein expression or catalytic activity. A surprisingly high
rate of homozygous mutations is found, with an unusually
high proportion of minor deletions and insertions. The data
for c.103delG indicates that this founder mutation is of north
European descent.
As PH II patients do not benefit from pyridoxine, as liver
transplantation to date has not been confirmed to correct the
hyperoxaluria, and as such patients may do reasonably well
with kidney transplant alone, distinguishing between type I
and type II PH is of paramount importance. Without careful
testing, patients may be misclassified, which may result in
inappropriate therapy.
NON-I, NON-II PH
The clinical phenotype of patients with non-I, non-II PH,
which account for approximately 5% of patients with PH, is
indistinguishable from that of type I and type II. Patients
typically have calcium oxalate stones beginning in infancy or
early childhood, marked hyperoxaluria that appears to persist
throughout life, normal enteric absorption of oxalate, and no
identifiable secondary causes of hyperoxaluria.33 The etiology
of the hyperoxaluria in non-I, non-II PH remains to be
elucidated. Studies of the SLC26A6 gene in a cohort of non-I,
non-II PH patients showed no sequence changes related to
oxalate transport.34 Indeed, as the diagnosis is one of
exclusion (patients have normal AGT and GRHPR enzyme
activity, and no identifiable cause of secondary hyperoxalur-
ia), it is unknown at present whether the patients described
represent one or several different disorders. Little is known of
the long-term outcome of patients with this form of primary
hyperoxaluria, as few patients have been well characterized to
date.33 Most patients have been diagnosed in infancy or early
childhood, with marked hyperoxaluria identified during
evaluation for urinary tract stones. To date, renal failure
has not been identified, although the mean age of the patients
described is quite young.
DIAGNOSTIC EVALUATION
Diagnostic evaluation should be conducted in a stepwise
manner beginning with ultrasound examination or other
imaging of the kidneys and urinary tract (Figure 1). In
patients with PH, nephrocalcinosis is a frequent finding in
infancy and early childhood, whereas later in life urolithiasis
without nephrocalcinosis is more often encountered.12,13
Oxalate should be measured, either in 24 h urines, or in ‘spot’
urine samples in infants and smaller children. The latter
values are expressed as (molar) creatinine ratios, for
which age-related normal values have been established
(35–37, Table 1). Significantly elevated values should be
repeated for confirmation. In patients with severe hyperox-
aluria (40.8 mmol/1.73 m2 per 24 h), glycolate (PH I) and L-
glyceric acid (PH type II) should also be determined. High
glycolate excretion is observed in many but not all patients
with PH type I. However, normal urine glycolate does not
exclude the diagnosis. Elevated urinary L-glyceric acid
excretion is found in nearly all patients with PH type II,
although occasional patients with normal L-glyceric acid
values have been reported.38 In PH type I, the urinary oxalate
excretion tends to be higher (2.14±1.29 mmol per 1.73 m2
per day) than in PH type II (1.46±0.49 mmol per 1.73 m2
per day), although the degree of overlap precludes its use for
diagnostic differentiation.32
In patients with good renal function, plasma oxalate
measurement is of little diagnostic benefit. However, plasma
oxalate, glycolate, and glycerate concentrations can be helpful
parameters in patients with ESRF. Plasma oxalate levels in
PH-ESRF patients are almost always higher (460–100mmol/l)
than those of non-PH-ESRF patients (20–60 mmol/l9). An
elevated plasma glycolate or glycerate level may be helpful for
distinguishing PH type I from type II disease.39–40 The
diagnosis can be confirmed by determination of AGT and
GRHPR enzyme activity in tissue from a percutaneous liver
biopsy. Diagnosis by liver biopsy is still considered the gold
standard. However, it is invasive and bears some risks (for
example, bleeding).
With advancing knowledge, molecular genetics has now
reached a level of sensitivity and specificity that makes it
feasible for definitive diagnostic testing.25 Screening of the
three most common mutations of AGXT detects both mutant
alleles in 34%, while direct sequencing can identify both
alleles in 95% of type I patients.41 In an index case with a
known mutation, carrier status can be quickly established. In
keeping with the autosomal recessive nature of PH types I
and II, carrier heterozygotes have normal urine oxalate
excretion, normal kidney function, and as far as is currently
known have an incidence of stone disease similar to that of
the general population.
Disadvantageous for mutation analysis is the fact that
mutations are distributed throughout the 11 exons of the AGXT
gene and more than 100 mutations have already been described.
A private mutation may appear only in one family. Therefore,
sequencing of all exons sometimes is necessary to identify both
mutated alleles and can be a time consuming process. Prenatal
diagnosis can be determined in patients with one or without
any mutation carrier status using linkage analysis of extra or
intragenic markers.28 For this purpose samples from several
family members, as well as of an index case with specific
diagnosis are necessary. Genotyping for type II PH has been less
complex, with only 15 mutations of GRHPR identified to date.
Genotyping for non-I, non-II PH is not possible, as no locus for
a responsible gene has yet been identified.
TREATMENT
Treatment should be initiated as soon as accurate and
reproducible baseline measurements of urine oxalate
excretion have been obtained. A large daily fluid intake
(43 l/1.73 m2 per day) is essential. If this is impossible,
placement of a gastrostomy tube should be considered to
ensure adequate fluid administration. In case of fever,
vomiting, diarrhea, or other significant fluid losses, patients
with PH should receive i.v. fluids. As only a very small
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proportion of urinary oxalate is derived from the diet in
patients with PH, dietary oxalate restriction is of limited
benefit.5 Nevertheless, nutrients extremely rich in oxalate and
an excessive intake of ascorbic acid, a precursor of oxalate,
should be avoided.
Pyridoxal phosphate is an essential cofactor of AGT, and
pharmacological doses of pyridoxine may significantly reduce
hyperoxaluria in some patients with type I PH. Approxi-
mately 30% of PH I patients have some degree of sensitivity
to pyridoxine.4,14,26 Patients with certain mutations, in
particular, respond to pyridoxine, and may even show
normalization of urinary oxalate.23,30 To assess pyridoxine
responsiveness (defined as 430% reduction in urinary
oxalate excretion), pyridoxine is started at a dose of 5 mg/
kg body weight per day. Recent data suggest that maximum
benefit is most likely to be achieved at less than 10 mg/kg per
day,28 although higher doses may occasionally be considered
on a trial basis. Occasionally, a much smaller daily dose
(10–20 mg) is also effective.4 A trial of at least 3–6 months of
pyridoxine, with effectiveness determined by measurement of
urinary oxalate excretion, is warranted in all PH I patients.
For those who respond favorably, pyridoxine should be
continued indefinitely or until liver transplantation. Evaluat-
ing pyridoxine response in patients who are in renal failure is
difficult. Many such patients lack urine output, and in those
who still have urine, other factors such as systemic oxalate
deposits may influence urine oxalate excretion. Genotyping
for mutations associated with pyridoxine response can be
helpful in such patients.
The aim of treatment with alkali citrate is the reduction of
the urinary calcium oxalate saturation.42 Citrate predominantly
binds to calcium, forming a soluble complex and reducing the
precipitation of calcium with other substances such as oxalate.
The daily dosage of alkali citrate is 0.1–0.15 g/kg body weight
(0.3–0.5 mmol/kg) of a sodium or sodium/potassium citrate
preparation. Citrate is metabolized in the liver to bicarbo-
nate, the alkali load leads to reduction of the intra-tubular
reabsorption of citrate and hence, more citrate is excreted
through the urine.43 Binding of calcium and citrate
complexes is further increased at a higher urinary pH. Alkali
citrate preparations lead to decreased stone production or
lesser expression of nephrocalcinosis.42 The effect of alkali
therapy, and the patient’s compliance, is checked by
measuring urinary pH and citrate excretion (determine both
parameters also before start of treatment). The therapeutic
effect of orthophosphate is comparable to that of alkali
citrate medication. Long-term follow-up reports of ortho-
phosphate treatment suggest efficacy for patients with PH.44
The role of the GI tract in oxalate physiology is becoming
better understood. A greater proportion of body oxalate
appears to be eliminated by the GI tract when renal function
is compromised. Colonic secretion and absorption of oxalate
are regulated by physiologic stimuli including the renin–
angiotensin system.23 Recently, the anion exchanger SLC26A6
has been shown to be involved in GI and renal oxalate
excretion in animal models.45 A role for SLC26A6 in human
oxalate excretion remains to be established. Although
abnormalities of SLC26A6 seem an attractive candidate as a
potential cause of non-I, non-II PH, or a modifier gene that
could influence disease expression in patients with PH types I
or II, work thus far does not suggest either.34 Certain
micro-organisms in the colon, such as Oxalobacter formigenes
contain enzymes that metabolize oxalate, reducing luminal
concentrations, and thus oxalate absorption. Oxalate secre-
tory pathways for intestinal oxalate elimination have also
been identified in the large intestine.46,47 A physiologic
interaction of O. formigenes with rat colonic mucosa to
modulate the handling of oxalate in colonized animals, with
induction of enteric secretion/excretion, has also been
described.48 This has led to the hypothesis that this organism
might be helpful in the treatment not only of patients with
secondary, but also with primary hyperoxaluria.48 A recent
pilot study has shown a reduction of urinary oxalate
excretion in the majority of PH patients treated with
Oxalobacter.49 Oral administration of Oxalobacter or oxalate
degrading enzymes is currently undergoing study as a
potential treatment.
RENAL REPLACEMENT THERAPY
With reduced capacity for renal clearance of excess oxalate
in chronic renal failure, hyperoxalemia and plasma super-
saturation for calcium oxalate ensue with risk of systemic
oxalosis. Therefore, specific renal replacement strategies are
required. When the GFR decreases to less than 30 ml/min per
Table 1 | Normal age-related values for urinary oxalate, glycolate, and L-glycerate excretion in 24 h urine expressed in mmol
(mg)/1.73 m2 body surface area per day and spot urine samples (expressed as molar creatinine ratio)
Parameter age Normal values
Oxalate o0.50 mmol (o45 mg)/1.73 m2 per day
Glycolate o0.50 mmol (o45 mg)/1.73 m2 per day
L-Glyceric acid o5 mmol/l
Molar creatinine ratios (mmol/mol) Oxalate Glycolate L-Glycerate
0–6 months o325–360 o363–425 14–205
7–24 months o132–174 o245–293 14–205
2–5 years o98–101 o191–229 14–205
5–14 years o70–82 o166–186 23–138
416 years o40 o99–125 o138
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1.73 m2, prompt renal replacement with transplantation or
dialysis is needed in most PH patients. Dialysis treatment
may need to be considered even earlier in some patients.50 If
dialysis is needed as a bridge to transplantation, intensive
dialysis, for example, hemodialysis on 5–6 days of the week
for 3–4 h per session plus nightly peritoneal dialysis, is often
needed to match daily oxalate production rates and thus
minimize the likelihood of systemic oxalosis.
In some patients with PH not even such intensive
regimens are able to remove sufficient oxalate.50–52 Therefore,
transplantation should be performed as early as possible.53
Doing so will reduce not only injurious effects of oxalate
on body tissues, but also the oxalate burden that must be
eliminated by the transplanted kidney.4
TRANSPLANTATION
Except for those patients with a complete response to
pyridoxine (normalizaton of urine oxalate), early disease
recurrence is a significant risk in isolated kidney transplanta-
tion in PH type I. Although reasonable outcomes of kidney-
only transplantation (including mostly living donors) were
observed in North America,54 this approach has largely been
replaced by combined liver/kidney transplantation. With the
metabolic defect in the liver and the problem being
overproduction of oxalate without other avenues for its
disposition, it is clearly necessary to perform total hepatect-
omy, even though the liver is normal in every other aspect.
Actuarial patient and liver allograft survivals at 5 years
following combined liver and kidney transplantation are 80
and 72%, respectively.53 Specific risk factors for renal graft
failure due to recurrent oxalosis are young age (o5 years)
and a long period on dialysis (42 years) before transplanta-
tion. The latter is related to the large body oxalate burden
that accumulates over time on dialysis.4,53 Administration of
very generous fluids and of alkali citrate or neutral phosphate
during the first months or even years after transplantation is
essential because of the slow mobilization of the accumulated
body calcium oxalate stores and thus persistent hyper-
oxaluria.55 The hyperoxaluria can cause injury to the renal
allograft and must be carefully managed until it resolves after
all oxalate stores have been mobilized and eliminated.56
Whether or not dialysis is performed for the first days after
transplantation depends on kidney graft function and degree
of hyperoxalemia and hyperoxaluria to which the trans-
planted kidney is exposed.
The rationale of pre-emptive liver transplantation, instead
of waiting until ESRF occurs, appears attractive at first look.57
However, the risk of losing a graft or even a patient who
might have lived many years longer without transplantation
raises serious ethical questions. Thus far, over a dozen
patients with PH I not in renal failure have been treated
with pre-emptive liver transplantation achieving reasonable
results.57 However, the heterogeneity of the disease has to be
kept in mind, when discussing a pre-emptive transplant
option, as patients may remain well and with stable kidney
function over many years under adequate treatment.
In patients with PH type II, the potential benefit of liver
transplantation is unclear. Hence, and as the disease most
often is not as severe as the type I PH, isolated kidney
transplantation is the treatment of choice in this group of
patients.
OUTLOOK
The long-term outlook for patients with PH has improved
substantially over the past two decades due to improved
understanding of the metabolic pathways, molecular genetics,
and pathophysiology of these inherited disorders. Recent
work elucidating the role of the GI tract in oxalate
elimination and the prospect of molecular stabilization of
mutant AGT leading to enhanced enzyme activity provide
exciting prospects for the future treatments. Knowledge of
the spectrum of disease expression, early diagnosis, and
initiation of treatment before renal failure ensues are essential
to realize the benefit for patients.
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